European Journal of Dermatology
MENULymphomatoid papulosis during upadaci-tinib treatment for rheumatoid arthritis Volume 32, numéro 1, January-February 2022
Illustrations
1 Department of Dermatology, Japanese Red Cross Kitami Hospital, Kitami, Japan
2 Department of Dermatology, Japanese Red Cross Kitami Hospital, Kitami, Japan
3 Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan
- DOI : 10.1684/ejd.2022.4238
- Page(s) : 142-3
- Année de parution : 2022
Upadacitinib is an orally administered selective Janus kinase 1 (JAK1) inhibitor that is highly effective against multiple inflammatory diseases, including rheumatoid arthritis (RA), psoriatic arthritis and atopic dermatitis. Janus kinase (JAK) inhibitors induce several adverse effects, such as herpes zoster, serious and opportunistic infections, and thromboembolic events. JAK inhibitors are also believed to increase the risk of malignancies, including lymphoproliferative disorders, by reducing antitumor [...]